Current and future trends in neoadjuvant immunotherapy for the treatment of triple-negative breast cancer

Descripción del Articulo

Triple-negative breast cancer (TNBC) comprises 15–20% of all breast cancers (BC). Lacking targeted therapy options, TNBC becomes the focal point of clinical investigations aiming not only to identify drugs with enhanced response potential but also to uncover new immunological and/or metabolic pathwa...

Descripción completa

Detalles Bibliográficos
Autores: de, Mello, RAB, Perez, KR, Vazquez, TP
Formato: revisión
Fecha de Publicación:2024
Institución:Instituto Nacional de Enfermedades Neoplásicas
Repositorio:INEN-Institucional
Lenguaje:inglés
OAI Identifier:oai:repositorio.inen.sld.pe:20.500.14703/390
Enlace del recurso:https: //doi.org/10.2217/imt-2022-0277
https://hdl.handle.net/20.500.14703/390
Nivel de acceso:acceso abierto
Materia:breast cancer
immunotherapy
neoadjuvant treatment
new targets
triple negative
https://purl.org/pe-repo/ocde/ford#3.02.21
Descripción
Sumario:Triple-negative breast cancer (TNBC) comprises 15–20% of all breast cancers (BC). Lacking targeted therapy options, TNBC becomes the focal point of clinical investigations aiming not only to identify drugs with enhanced response potential but also to uncover new immunological and/or metabolic pathways conducive to more effective treatments. Currently, neoadjuvant treatment for TNBC relies on standard chemotherapy in conjunction with immunotherapy, given the improved response observed with this drug combination. This review delves into the latest therapeutic updates in TNBC treatment and explores potential advancements shaping the future landscape of this disease in the neoadjuvant setting.
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).